Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker NVAX · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Oct 23, 2026 | Efficacy and Safety of NVX-CoV2705 NCT07086222 · COVID-19, Sars-CoV-2 Infection NVX-CoV2705, Placebo | NVAX Novavax | Phase 4 | Terminated | 6,500 | Oct 9, 2026 | Registry ↗ |
| Jun 5, 2026 | A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vac… NCT06291857 · COVID-19 CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M… | NVAX Novavax | Phase 3 | Completed | 9,320 | Dec 24, 2025 | Registry ↗ |
| Jun 2, 2026 | Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Respon… NCT06633835 · COVID-19, Vaccine-Preventable Diseases protein subunit: Novavax COVID-19 vaccine, Pfizer mRNA COVI… | NVAX Novavax | Phase 4 | Completed | 660 | Dec 30, 2024 | Registry ↗ |
| May 22, 2026 | Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years NCT05468736 · COVID-19 SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Perio… | NVAX Novavax | Phase 2/3 | Completed | 3,600 | Jan 16, 2024 | Registry ↗ |
| Apr 17, 2026 | Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults NCT05463068 · COVID-19, SARS-CoV-2 Infection NVX-Cov2373 | NVAX Novavax | Phase 3 | Completed | 911 | Aug 17, 2022 | Registry ↗ |
| Jul 18, 2025 | A Strain Change Study for SARS-CoV-2 rS Vaccines NCT06409663 · Severe Acute Respiratory Syndrome Coronavirus 2 Infection NVX-CoV2705 Vaccine | NVAX Novavax | Phase 3 | Completed | 60 | Oct 15, 2024 | Registry ↗ |
| Jul 15, 2025 | Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines NCT05973006 · COVID-19 NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vac… | NVAX Novavax | Phase 3 | Completed | 400 | Apr 1, 2024 | Registry ↗ |
| Jun 26, 2025 | Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines NCT05875701 · COVID-19 NVX-CoV2373, SARS-CoV-2 rS antigen/Matrix-M Adjuvant | NVAX Novavax | Phase 3 | Completed | 147 | Nov 11, 2023 | Registry ↗ |
| May 8, 2025 | A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults i… NCT04583995 · SARS-CoV-2 Infection, COVID-19 SARS-CoV-2 rS/Matrix M1-Adjuvant, Placebo | NVAX Novavax | Phase 3 | Completed | 15,185 | Mar 29, 2022 | Registry ↗ |
| May 6, 2025 | A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal I… NCT02624947 · Respiratory Syncytial Virus Infections RSV F vaccine with adjuvant, Formulation buffer | NVAX Novavax | Phase 3 | Completed | 4,636 | Dec 28, 2018 | Registry ↗ |
| Apr 10, 2025 | Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine NCT04961541 · SARS-CoV Infection, Covid19 ICC Vaccine, qNIV Nanoparticle Vaccine2 in-clinic mixed wit… | NVAX Novavax | Phase 1/2 | Completed | 637 | Dec 22, 2021 | Registry ↗ |
| Mar 11, 2025 | Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine NCT06485752 · COVID-19 tNIV 1 and Matrix-M Adjuvant | NVAX Novavax | Phase 2/3 | Withdrawn | 0 | Feb 4, 2025 | Registry ↗ |
| Mar 11, 2025 | Lot Consistency Study of COVID-19 and Influenza Combination Vaccine NCT06482359 · COVID-19, Influenza coformulated CIC Vaccine, Fluzone HD trivalent | NVAX Novavax | Phase 2/3 | Withdrawn | 0 | Nov 16, 2025 | Registry ↗ |
| Dec 13, 2024 | Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccin… NCT05925127 · COVID-19 NVX-CoV2373 (5μg), NVX-CoV2601 (5μg) | NVAX Novavax | Phase 2/3 | Completed | 994 | May 21, 2024 | Registry ↗ |
| Jul 16, 2024 | A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine NCT05519839 · COVID-19, Influenza qNIV Vaccine with Matrix-M Adjuvant, Influenza Vaccine | NVAX Novavax | Phase 2 | Completed | 1,579 | Jul 25, 2023 | Registry ↗ |
| May 30, 2024 | A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Boost… NCT05975060 · COVID-19 XBB.1.5 Vaccine (Booster), XBB.1.5 Vaccine (single dose) | NVAX Novavax | Phase 2/3 | Completed | 660 | Nov 15, 2023 | Registry ↗ |
| Apr 23, 2024 | Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines NCT05372588 · COVID-19, SARS CoV 2 Infection NVX-CoV2515, NVX-Cov2373 | NVAX Novavax | Phase 3 | Completed | 1,340 | Jul 17, 2022 | Registry ↗ |
| Dec 21, 2023 | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18… NCT04611802 · SARS-CoV Infection, Covid19 SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Perio… | NVAX Novavax | Phase 3 | Completed | 33,000 | Apr 10, 2023 | Registry ↗ |
| May 6, 2023 | Phase 3 Pivotal Trial of NanoFlu™ in Older Adults NCT04120194 · Influenza, Human NanoFlu, Fluzone Quadrivalent | NVAX Novavax | Phase 3 | Completed | 2,654 | Oct 29, 2020 | Registry ↗ |
| Apr 10, 2023 | Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Ma… NCT04368988 · COVID-19 SARS-CoV-2 rS - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant -… | NVAX Novavax | Phase 1/2 | Completed | 1,419 | Jun 1, 2022 | Registry ↗ |
| Mar 16, 2023 | A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Ri… NCT05112848 · SARS-CoV-2 Infection NVX-CoV2373 | NVAX Novavax | Phase 2 | Completed | 384 | May 23, 2022 | Registry ↗ |
| Dec 21, 2022 | Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vacci… NCT03293498 · Influenza NanoFlu, Fluzone HD - Day 0 | NVAX Novavax | Phase 1/2 | Completed | 330 | Mar 14, 2018 | Registry ↗ |
| Nov 4, 2022 | Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults NCT03658629 · Influenza, Human NanoFlu (Quad-NIV), Matrix-M Adjuvant | NVAX Novavax | Phase 2 | Terminated | 1,375 | Apr 26, 2019 | Registry ↗ |
| Jul 19, 2022 | A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults NCT02608502 · Respiratory Syncytial Virus (RSV) RSV-F Vaccine, Phosphate Buffer Placebo | NVAX Novavax | Phase 3 | Completed | 11,850 | Dec 2016 | Registry ↗ |
| May 31, 2022 | Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVI… NCT05029856 · Covid19 SII B.1.351, SII B.1.351 | NVAX Novavax | Phase 1/2 | Withdrawn | 0 | Aug 2022 | Registry ↗ |
| May 27, 2022 | Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vac… NCT02593071 · Respiratory Syncytial Virus (RSV) RSV-F Vaccine, Phosphate Buffer Placebo | NVAX Novavax | Phase 2 | Completed | 1,330 | Nov 2016 | Registry ↗ |
| May 27, 2022 | Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly… NCT02266628 · Respiratory Syncytial Virus (RSV) RSV-F Vaccine, Saline Placebo | NVAX Novavax | Phase 2 | Completed | 1,599 | Mar 2016 | Registry ↗ |
| May 27, 2022 | RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women. NCT02247726 · Respiratory Syncytial Virus Infections Saline Placebo (0.5mL injection), RSV F vaccine (0.5mL inje… | NVAX Novavax | Phase 2 | Completed | 50 | Jul 2016 | Registry ↗ |
| Feb 17, 2022 | A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults NCT04533399 · SARS-CoV-2 Infection, COVID-19 SARS-CoV-2 rS/Matrix-M1 Adjuvant, Placebo | NVAX Novavax | Phase 2 | Completed | 4,422 | Dec 7, 2021 | Registry ↗ |
| Dec 6, 2021 | Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and… NCT03026348 · Respiratory Syncytial Viruses RSV F Vaccine with Aluminum Phosphate Adjuvant, RSV F Vacci… | NVAX Novavax | Phase 2 | Completed | 300 | Apr 2017 | Registry ↗ |
| Nov 24, 2021 | Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine… NCT02370589 · Ebola Base Dose EBOV GP Vaccine, 2x Base Dose EBOV GP Vaccine | NVAX Novavax | Phase 1 | Completed | 230 | Apr 2016 | Registry ↗ |
| Sep 23, 2016 | Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults NCT02307851 · Influenza Quadrivalent VLP Vaccine, Comparator TIV | NVAX Novavax | Phase 2 | Completed | 400 | Jun 2015 | Registry ↗ |
| Sep 23, 2016 | A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant NCT02078674 · Influenza (Pandemic) Monovalent Avian Influenza VLP (H7N9), Matrix-M1™ adjuvant | NVAX Novavax | Phase 1/2 | Completed | 610 | Jul 2015 | Registry ↗ |
| May 26, 2016 | RSV F Dose-Ranging Study in Women NCT01960686 · Respiratory Syncytial Virus Infections Low dose RSV F Antigen, High dose RSV F Antigen | NVAX Novavax | Phase 2 | Completed | 720 | Apr 2014 | Registry ↗ |
| Apr 28, 2016 | A Phase I Randomized, Observer-Blinded, Dose-Ranging Study in Healthy Subjects 24 to <72 Months of… NCT02296463 · Respiratory Synctial Virus RSV F Vaccine with adjuvant (0.5mL injection), RSV F Vaccin… | NVAX Novavax | Phase 1 | Completed | 32 | Sep 2015 | Registry ↗ |
35 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:20 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances